Aptevo Therapeutics

(NASDAQ) APVO

Current Price$4.72

Market Cap$5.88M

Since IPO (2016)-100%

5 Year-100%

1 Year-95%

1 Month-4%

Aptevo Therapeutics Financials at a Glance

Market Cap

$5.88M

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.26M

EPS (TTM)

-$203.74

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$4.72

Volume

28,427.925

Open

$5.03

Price

$4.72

Volume

28,427.925

Open

$5.03

Previous Close

$4.72

Daily Range

$4.71 - $5.03

52-Week Range

$3.80 - $235.98

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$4.72

Volume

28,427.925

Open

$5.03

Previous Close

$4.72

Daily Range

$4.71 - $5.03

52-Week Range

$3.80 - $235.98

Estimated Earnings Date

Aug 6, 2026

APVO News

Aptevo Reports 85% Remission in Q2

Motley Fool Markets TeamAug 11, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aptevo Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Marvin L. White, MBA

Website

www.aptevotherapeutics.com

Headquarters

Seattle, WA 98121, US

APVO Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-549%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.88M

Shares Outstanding

1.25M

Volume

28.43K

Avg. Volume

56.47K

Financials (TTM)

Gross Profit

-$240.00K

Operating Income

-$26.31M

EBITDA

-$26.07M

Operating Cash Flow

-$25.59M

Capital Expenditure

$0.00

Free Cash Flow

-$25.59M

Cash & ST Invst.

$21.62M

Total Debt

$4.63M

Aptevo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$35.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.88M

N/A

Market Cap/Employee

$158.96K

N/A

Employees

N/A

Net Income

-$6.70M

-4.5%

EBITDA

-$6.80M

-6.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$10.10M

+542.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.53M

-20.2%

Short Term Debt

$892.00K

N/A

Return on Assets

-1.32%

N/A

Return on Invested Capital

-1.76%

N/A

Free Cash Flow

-$7.97M

-21.1%

Operating Cash Flow

-$7.97M

-21.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BCDABioCardia, Inc.

BCDABioCardia, Inc.$1.03+12.08%

RADXRadiopharm Theranostics Limited

RADXRadiopharm Theranostics Limited$4.32-6.70%

INABIN8bio, Inc.

INABIN8bio, Inc.$1.45-5.23%

HCWBHCW Biologics Inc.

HCWBHCW Biologics Inc.$1.63+0.00%

ERNAErnexa Therapeutics Inc.

ERNAErnexa Therapeutics Inc.$7.89-3.66%

EPIXESSA Pharma Inc.

EPIXESSA Pharma Inc.$0.20-1.85%

ABPAbpro Corporation

ABPAbpro Corporation$0.52+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$14.38-0.13%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.05-0.14%

KEELKeel Infrastructure

KEELKeel Infrastructure$5.13-0.13%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.19+0.14%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.14-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.50+0.02%

MRVLMarvell Technology

MRVLMarvell Technology$263.47-0.17%

Questions About APVO

What is the current price of Aptevo Therapeutics?

Aptevo Therapeutics is trading at $4.72 per share.

What is the 52-week range for Aptevo Therapeutics?

Over the past 52 weeks, Aptevo Therapeutics has traded between $3.80 and $235.98.

How much debt does Aptevo Therapeutics have?

As of the most recent reporting period, Aptevo Therapeutics reported total debt of $4.42M.

How much cash does Aptevo Therapeutics have on hand?

Aptevo Therapeutics reported $14.53M in cash and cash equivalents in its most recent financial results.

What is Aptevo Therapeutics’s dividend yield?

Aptevo Therapeutics does not currently have a dividend yield.

Aptevo Therapeutics

Aptevo Therapeutics Financials at a Glance

APVO News

Aptevo Reports 85% Remission in Q2

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Aptevo Therapeutics

APVO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Aptevo Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About APVO

What is the current price of Aptevo Therapeutics?

What is the 52-week range for Aptevo Therapeutics?

How much debt does Aptevo Therapeutics have?

How much cash does Aptevo Therapeutics have on hand?

What is Aptevo Therapeutics’s dividend yield?

Premium Investing Services